Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787956 | 0.93 | MCHR1 (0.51) | MCHR1SSTR5SIGMAR1DRD4POLB | |
| SCHEMBL1786965 | 0.90 | MCHR1 (0.52) | MCHR1SSTR5SIGMAR1DRD4POLB | |
| SCHEMBL1786793 | 0.86 | MCHR1 (0.50) | MCHR1SSTR5SIGMAR1DRD4POLB | |
| SCHEMBL1790544 | 0.83 | SSTR5 (0.57) | MCHR1SSTR5DRD4POLB | |
| SCHEMBL1788399 | 0.80 | MCHR1 (0.58) | MCHR1SSTR5SIGMAR1DRD4 | |
| SCHEMBL12614652 | 0.79 | SSTR5 (0.58) | MCHR1SSTR5POLBUSP2 | |
| SCHEMBL1786527 | 0.78 | SSTR5 (0.54) | MCHR1SSTR5DRD4POLB | |
| Formic Acid SCHEMBL1785841 | 0.77 | SSTR5 (0.52) | MCHR1SSTR5SIGMAR1DRD4POLB | |
| SCHEMBL1787892 | 0.75 | SSTR5 (0.55) | MCHR1SSTR5DRD4POLB | |
| SCHEMBL1787380 | 0.75 | SSTR5 (0.55) | MCHR1SSTR5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2319841-A1 | (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE | MSD K.K. (JP) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | MCHR1, MC5R, MCHR2 | MCHR1 1/4885SSTR5 22/4885SIGMAR1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.